Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Genetic Research » Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Veracyte's Prosigna IDs Breast Cancer Patients Likely to Benefit from Aggressive Chemotherapy

Mar 02, 2020
|
staff reporter

NEW YORK – A new retrospective study published in NPJ Breast Cancer on Monday suggests that Veracyte's Prosigna breast cancer prognostic gene signature assay can identify the subgroups of patients who are more likely to benefit from aggressive chemotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Changes to the Lancet's Process

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

Emails Show Pressure on CDC

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

Into One System

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

PLOS Papers on Dilated Cardiomyopathy, Lung Cancer Epigenetics, Pediatric Staphylococcus aureus Infections

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.

What's Popular?

In Genetic Research

  1. MSK Clonal Hematopoiesis Clinic Aims to Drive New Strategies for Cancer Risk Assessment, Prevention

    Premium

  2. Willingness to Donate DNA to Research Is Low, Global Survey Finds

  3. Viking Age Human Migrations Untangled Through Ancient DNA Analysis

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.